Minh-Phuong Huynh-Le1, Tor Åge Myklebust2,3, Christine H Feng1, Roshan Karunamuni1, Tom Børge Johannesen2, Anders M Dale4, Ole A Andreassen5, Tyler M Seibert1,6. 1. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California. 2. Department of Registration, Cancer Registry of Norway, Oslo, Norway. 3. Department of Research and Innovation, Møre and Romsdal Hospital Trust, Alesund, Norway. 4. Department of Neurosciences, University of California San Diego, La Jolla, California. 5. NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 6. Department of Bioengineering, University of California San Diego, La Jolla, California.
Abstract
BACKGROUND: Optimal prostate cancer (PCa) screening strategies will focus on men likely to have potentially lethal disease. Age-specific incidence rates (ASIRs) by modern clinical risk groups could inform risk stratification efforts for screening. METHODS: This cross-sectional population study identified all men diagnosed with PCa in Norway from 2014 to 2017 (n = 20,356). Age, Gleason score (primary plus secondary), and clinical stage were extracted. Patients were assigned to clinical risk groups: low, favorable intermediate, unfavorable intermediate, high, regional, and metastatic. Chi-square tests analyzed the independence of Gleason scores and modern PCa risk groups with age. ASIRs for each risk group were calculated as the product of Norwegian ASIRs for all PCa and the proportions observed for each risk category. RESULTS: Older age was significantly associated with a higher Gleason score and more advanced disease. The percentages of men with Gleason 8 to 10 disease among men aged 55 to 59, 65 to 69, 75 to 79, and 85 to 89 years were 16.5%, 23.4%, 37.2%, and 59.9%, respectively (P < .001); the percentages of men in the same age groups with at least high-risk disease were 29.3%, 39.1%, 60.4%, and 90.6%, respectively (P < .001). The maximum ASIRs (per 100,000 men) for low-risk, favorable intermediate-risk, unfavorable intermediate-risk, high-risk, regional, and metastatic disease were 157.1 for those aged 65 to 69 years, 183.8 for those aged 65 to 69 years, 194.8 for those aged 70 to 74 years, 408.3 for those aged 75 to 79 years, 159.7 for those aged ≥85 years, and 314.0 for those aged ≥85 years, respectively. At the ages of 75 to 79 years, the ASIR of high-risk disease was approximately 6 times greater than the ASIR at 55 to 59 years. CONCLUSIONS: The risk of clinically significant localized PCa increases with age. Healthy older men may benefit from screening.
BACKGROUND: Optimal prostate cancer (PCa) screening strategies will focus on men likely to have potentially lethal disease. Age-specific incidence rates (ASIRs) by modern clinical risk groups could inform risk stratification efforts for screening. METHODS: This cross-sectional population study identified all men diagnosed with PCa in Norway from 2014 to 2017 (n = 20,356). Age, Gleason score (primary plus secondary), and clinical stage were extracted. Patients were assigned to clinical risk groups: low, favorable intermediate, unfavorable intermediate, high, regional, and metastatic. Chi-square tests analyzed the independence of Gleason scores and modern PCa risk groups with age. ASIRs for each risk group were calculated as the product of Norwegian ASIRs for all PCa and the proportions observed for each risk category. RESULTS: Older age was significantly associated with a higher Gleason score and more advanced disease. The percentages of men with Gleason 8 to 10 disease among men aged 55 to 59, 65 to 69, 75 to 79, and 85 to 89 years were 16.5%, 23.4%, 37.2%, and 59.9%, respectively (P < .001); the percentages of men in the same age groups with at least high-risk disease were 29.3%, 39.1%, 60.4%, and 90.6%, respectively (P < .001). The maximum ASIRs (per 100,000 men) for low-risk, favorable intermediate-risk, unfavorable intermediate-risk, high-risk, regional, and metastatic disease were 157.1 for those aged 65 to 69 years, 183.8 for those aged 65 to 69 years, 194.8 for those aged 70 to 74 years, 408.3 for those aged 75 to 79 years, 159.7 for those aged ≥85 years, and 314.0 for those aged ≥85 years, respectively. At the ages of 75 to 79 years, the ASIR of high-risk disease was approximately 6 times greater than the ASIR at 55 to 59 years. CONCLUSIONS: The risk of clinically significant localized PCa increases with age. Healthy older men may benefit from screening.
Authors: R G H M Cremers; H E Karim-Kos; S Houterman; R H A Verhoeven; F H Schröder; T H van der Kwast; P J M Kil; J W W Coebergh; L A L M Kiemeney Journal: Eur J Cancer Date: 2010-05-12 Impact factor: 9.162
Authors: Donna P Ankerst; Josef Hoefler; Sebastian Bock; Phyllis J Goodman; Andrew Vickers; Javier Hernandez; Lori J Sokoll; Martin G Sanda; John T Wei; Robin J Leach; Ian M Thompson Journal: Urology Date: 2014-06 Impact factor: 2.649
Authors: Andrew M D Wolf; Richard C Wender; Ruth B Etzioni; Ian M Thompson; Anthony V D'Amico; Robert J Volk; Durado D Brooks; Chiranjeev Dash; Idris Guessous; Kimberly Andrews; Carol DeSantis; Robert A Smith Journal: CA Cancer J Clin Date: 2010-03-03 Impact factor: 508.702
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja Journal: BMJ Date: 2013-04-15
Authors: Minh-Phuong Huynh-Le; Roshan Karunamuni; Chun Chieh Fan; Lui Asona; Wesley K Thompson; Maria Elena Martinez; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth R Muir; Artitaya Lophatananon; Johanna Schleutker; Nora Pashayan; Jyotsna Batra; Henrik Grönberg; David E Neal; Børge G Nordestgaard; Catherine M Tangen; Robert J MacInnis; Alicja Wolk; Demetrius Albanes; Christopher A Haiman; Ruth C Travis; William J Blot; Janet L Stanford; Lorelei A Mucci; Catharine M L West; Sune F Nielsen; Adam S Kibel; Olivier Cussenot; Sonja I Berndt; Stella Koutros; Karina Dalsgaard Sørensen; Cezary Cybulski; Eli Marie Grindedal; Florence Menegaux; Jong Y Park; Sue A Ingles; Christiane Maier; Robert J Hamilton; Barry S Rosenstein; Yong-Jie Lu; Stephen Watya; Ana Vega; Manolis Kogevinas; Fredrik Wiklund; Kathryn L Penney; Chad D Huff; Manuel R Teixeira; Luc Multigner; Robin J Leach; Hermann Brenner; Esther M John; Radka Kaneva; Christopher J Logothetis; Susan L Neuhausen; Kim De Ruyck; Piet Ost; Azad Razack; Lisa F Newcomb; Jay H Fowke; Marija Gamulin; Aswin Abraham; Frank Claessens; Jose Esteban Castelao; Paul A Townsend; Dana C Crawford; Gyorgy Petrovics; Ron H N van Schaik; Marie-Élise Parent; Jennifer J Hu; Wei Zheng; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert Journal: Prostate Cancer Prostatic Dis Date: 2022-02-12 Impact factor: 5.455
Authors: Minh-Phuong Huynh-Le; Chun Chieh Fan; Roshan Karunamuni; Eleanor I Walsh; Emma L Turner; J Athene Lane; Richard M Martin; David E Neal; Jenny L Donovan; Freddie C Hamdy; J Kellogg Parsons; Rosalind A Eeles; Douglas F Easton; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch Garcia; Kenneth Muir; Henrik Grönberg; Fredrik Wiklund; Markus Aly; Johanna Schleutker; Csilla Sipeky; Teuvo Lj Tammela; Børge Grønne Nordestgaard; Timothy J Key; Ruth C Travis; Paul D P Pharoah; Nora Pashayan; Kay-Tee Khaw; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Dominika Wokolorczyk; Wojciech Kluzniak; Lisa A Cannon-Albright; Hermann Brenner; Ben Schöttker; Bernd Holleczek; Jong Y Park; Thomas A Sellers; Hui-Yi Lin; Chavdar Kroumov Slavov; Radka P Kaneva; Vanio I Mitev; Jyotsna Batra; Judith A Clements; Amanda B Spurdle; Manuel R Teixeira; Paula Paulo; Sofia Maia; Hardev Pandha; Agnieszka Michael; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-24 Impact factor: 4.254
Authors: Minh-Phuong Huynh-Le; Chun Chieh Fan; Roshan Karunamuni; Wesley K Thompson; Maria Elena Martinez; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth Muir; Johanna Schleutker; Nora Pashayan; Jyotsna Batra; Henrik Grönberg; David E Neal; Jenny L Donovan; Freddie C Hamdy; Richard M Martin; Sune F Nielsen; Børge G Nordestgaard; Fredrik Wiklund; Catherine M Tangen; Graham G Giles; Alicja Wolk; Demetrius Albanes; Ruth C Travis; William J Blot; Wei Zheng; Maureen Sanderson; Janet L Stanford; Lorelei A Mucci; Catharine M L West; Adam S Kibel; Olivier Cussenot; Sonja I Berndt; Stella Koutros; Karina Dalsgaard Sørensen; Cezary Cybulski; Eli Marie Grindedal; Florence Menegaux; Kay-Tee Khaw; Jong Y Park; Sue A Ingles; Christiane Maier; Robert J Hamilton; Stephen N Thibodeau; Barry S Rosenstein; Yong-Jie Lu; Stephen Watya; Ana Vega; Manolis Kogevinas; Kathryn L Penney; Chad Huff; Manuel R Teixeira; Luc Multigner; Robin J Leach; Lisa Cannon-Albright; Hermann Brenner; Esther M John; Radka Kaneva; Christopher J Logothetis; Susan L Neuhausen; Kim De Ruyck; Hardev Pandha; Azad Razack; Lisa F Newcomb; Jay H Fowke; Marija Gamulin; Nawaid Usmani; Frank Claessens; Manuela Gago-Dominguez; Paul A Townsend; William S Bush; Monique J Roobol; Marie-Élise Parent; Jennifer J Hu; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert Journal: Nat Commun Date: 2021-02-23 Impact factor: 14.919
Authors: Minh-Phuong Huynh-Le; Roshan Karunamuni; Chun Chieh Fan; Wesley K Thompson; Kenneth Muir; Artitaya Lophatananon; Karen Tye; Alicja Wolk; Niclas Håkansson; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert Journal: Prostate Cancer Prostatic Dis Date: 2021-03-15 Impact factor: 5.554